10Mar 2024
Omalizumab for the Treatment of Multiple Food Allergies

Omalizumab for the Treatment of Multiple Food Allergies

A trial investigated omalizumab, an anti-IgE antibody, as monotherapy for multiple food allergies, particularly peanut allergy. Participants aged 1 to 55 with peanut allergy and reactions to other specified foods were studied. Omalizumab or placebo was administered every 2 to 4 weeks for 16 to 20 weeks. Omalizumab significantly increased the threshold for peanut and other food allergens compared to placebo. Of 118 omalizumab recipients, 67% met primary endpoint criteria versus 7% of placebo recipients. Key secondary endpoints also favored omalizumab. Safety profiles were similar, with more injection-site reactions in the omalizumab group. The study suggests omalizumab's potential in managing multiple food allergies.

  • #dermatology

Like

Save

Share